Evidence map›Paper›PMID 25761309›Full record

Trial reportBlood transfusion = Trasfusione del sangue2015

A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

Giovanni F Torelli, Carmela Rozera, Laura Santodonato, Nadia Peragine, Giuseppina D'agostino, Enrica Montefiore, Maria R Napolitano, Domenica M Monque, Davide Carlei, Paola Mariglia and 7 more

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood transfusion = Trasfusione del sangue, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Oncology letters · 2018
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Giovanni F TorelliHaematology, Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.
Carmela RozeraDepartment of Haematology, Oncology and Molecular Medicine, National Institute of Health, Rome, Italy.
Laura SantodonatoDepartment of Haematology, Oncology and Molecular Medicine, National Institute of Health, Rome, Italy.
Nadia PeragineHaematology, Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.
Giuseppina D'agostinoDepartment of Haematology, Oncology and Molecular Medicine, National Institute of Health, Rome, Italy.
Enrica MontefioreDepartment of Haematology, Oncology and Molecular Medicine, National Institute of Health, Rome, Italy.
Maria R NapolitanoDepartment of Haematology, Oncology and Molecular Medicine, National Institute of Health, Rome, Italy.
Domenica M MonqueDepartment of Haematology, Oncology and Molecular Medicine, National Institute of Health, Rome, Italy.
Davide CarleiDepartment of Haematology, Oncology and Molecular Medicine, National Institute of Health, Rome, Italy.
Paola MarigliaHaematology, Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.
Simona PauselliHaematology, Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.
Maria GozzerTransfusion Centre, Department of Molecular Medicine, Sapienza University, Rome, Italy.
Mahnaz Shafii BaftiTransfusion Centre, Department of Molecular Medicine, Sapienza University, Rome, Italy.
Gabriella GirelliTransfusion Centre, Department of Molecular Medicine, Sapienza University, Rome, Italy.
Anna GuariniHaematology, Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.
Filippo BelardelliDepartment of Haematology, Oncology and Molecular Medicine, National Institute of Health, Rome, Italy.
Robin FoàHaematology, Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGreat interest has been raised recently by the design of new adoptive immunotherapeutic strategies based on the in vivo infusion of ex vivo-expanded and activated natural killer (NK) cells. The development of good manufacturing practice (GMP) methods for the efficient production of fully functional NK cells is mandatory for clinical application. MATERIALS AND

methodsPeripheral blood mononuclear cells were obtained by leukapheresis and processed in the GMP facility. For NK-cell enrichment, a two-step immunomagnetic procedure consisting of CD3(+) T-cell depletion followed by CD56(+) cell positive selection was used. Isolated NK cells were suspended in serum-free medium containing autologous plasma, interleukin (IL)-2 and IL-15 in the presence of irradiated autologous feeder cells and cultured for 14 days at 37 °C. IL-2 and IL-15 were also added during the last 24 hours of culture. Expanded cells underwent full quality control testing for cytogenetic characteristics, viability, sterility, phenotype and endotoxin status; functional tests, such as degranulation assays and cytotoxicity, were performed on expanded NK cells before cryopreservation and after thawing.

resultsNK-cell populations expanded on average 15.7±4.7 fold by day 14, with a viability of 96% ±0.5. At the end of the incubation period, 97% ±1.1 of the expanded population was CD56(+) NK cells; these effector cells showed significant up-regulation of the activating receptors NKG2D and DNAM-1. Functional tests demonstrated that expanded NK cells are fully functional with no difference whether tested before cryopreservation or after thawing. DISCUSSION: These data provide the basis for developing new NK-cell-based immunotherapeutic strategies for the treatment of patients with cancer.

Indexed as

Cell Culture TechniquesCryopreservationFemaleHumansKiller Cells, NaturalLeukapheresisMale

Identifiers

PMID25761309
PMCPMC4614300
OpenAlexW5014644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.